MedTrace Logo

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

NCT02749825 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2016-04-25

No results posted yet for this study

Summary

This research study looks at Testosterone levels in patients receiving Trelstar versus those receiving Lupron or Zoladex. These drugs have been approved for treatment of Prostate Cancer by the FDA.

Conditions

Interventions

DRUG

Trelstar

As labeled

DRUG

Lupron

As labeled

DRUG

Zoladex

As labeled

Sponsors & Collaborators

  • Manyak, Michael, M.D.

    collaborator INDIV

  • Watson Pharmaceuticals

    collaborator INDUSTRY

  • Pharmatech

    lead INDUSTRY

Principal Investigators

  • Michael Michael Manyak, MD · Georege Washington University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2006-05-31
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02749825 on ClinicalTrials.gov